1 option
Clinical review report Semaglutide (Ozempic) (Novo Nordisk Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Outcome assessment (Medical care).
- Diabetes--Treatment.
- Diabetes.
- Physical Description:
- 1 online resource (1 PDF file (149 pages)) : illustrations
- Other Title:
- Clinical review report Semaglutide
- Place of Publication:
- Ottawa, Ontario : Canadian Agency for Drugs and Technologies in Health, 2019.
- Summary:
- The objective of this review was to perform a systematic review of the beneficial and harmful effects of semaglutide (SEM) at the recommended dose for the treatment of adult patients with Type 2 diabetes mellitus.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.